Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

Non-alcoholic fatty liver disease (NAFLD) has emerged pandemically across the globe and
particularly affects patients with obesity and type 2 diabetes. NAFLD is a complex systemic …

Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions worldwide.
NAFLD and type 2 diabetes mellitus (T2DM) are known to frequently coexist and act …

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …

Background Non-alcoholic fatty liver disease, or as recently proposed 'metabolic-associated
fatty liver disease'(MAFLD), is characterized by pathological accumulation of triglycerides …

Successful development of treatments for non-alcoholic fatty liver disease and its
progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. Because …

Nonalcoholic steatohepatitis (NASH), a chronic liver disease without an approved therapy, is
associated with lipotoxicity and insulin resistance and is a major cause of cirrhosis and …

Nonalcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver
disease worldwide and is strongly associated with the presence of oxidative stress …

The global prevalence of nonalcoholic fatty liver disease (NAFLD) has dramatically
increased in parallel with the epidemic of obesity. Controversy has emerged around dietary …